HOCOMA ANNOUNCES FIRST EARLY REHABILITATION ROBOTIC DEVICE WITH INTEGRATED FUNCTIONAL ELECTRICAL STIMULATION
14th November 2012
14th November 2012
For Non-US media only. The Swiss-based medical technology company Hocoma presents the next generation of its early rehabilitation device Erigo® at the Medica in Düsseldorf from November 14 to 17, 2012. As the first system that combines robotic verticalization with functional electrical stimulation (FES), the device allows an even more effective early mobilization of neurological and bed-ridden patients. With its advanced new features, the Erigo is designed for a broader use in acute care.
Hocoma was set up in 2000, as a spin-off of the Swiss University Hospital Balgrist. The company currently employs more than 120 people at its headquarters near Zurich, Switzerland and at its subsidiaries in the US and Singapore. Hocoma develops and produces therapy solutions for neurological patients with movement disorders caused by stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy or other neurological diseases and injuries as well as for low back pain patients. The product range features devices for intensive locomotion therapy (Lokomat®), functional therapy of the upper extremities (Armeo®), early rehabilitation and patient mobilization (Erigo®) as well as functional movement therapy within low back pain treatment (Valedo®). Hocoma’s products are applied successfully in clinics and research institutes worldwide. This medical technology company has received many awards, and was honored with the “Red Herring 100 Global Award” in January 2010, as one of the hundred most innovative companies worldwide. Hocoma generated a turnover of more than 27 million CHF in 2011. Dr. Gery Colombo is the CEO of Hocoma AG.
1 Schweickert WD, Pohlman MC, Pohlman AS et al. (2009) Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. The Lancet 373 (9678):1874-1882
2 Cumming TB, Thrift AG, Collier JM et al. (2011) Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke 42(1):153-158
3 Luther MS, Krewer C, Muller F, Koenig E (2008) Comparison of orthostatic reactions of patients still unconscious within the first three months of brain injury on a tilt table with and without integrated stepping. A prospective, randomized crossover pilot trial. Clin Rehabil 22:1034-1041.
4 Morris PE et al (2008) Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Crit Care Med 36(8):2238-2243. 5 Yoshida T, Masani K, Sayenko D, Miyatani M, Fisher J, Popovic M (2012) Cardiovascular Response of Individuals With Spinal Cord Injury to Dynamic Functional Electrical Stimulation Under Orthostatic Stress. IEEE Trans Neural Syst Rehabil Eng. 2012 Aug 9. [Epub ahead of print].
All Hocoma products are medical devices and must be used in strict adherence to the User Manual; failure to do so may result in serious personal injury. It is strongly recommended that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes) for the latest available information. Please contact Hocoma should you have any questions.
Use only under the supervision of qualified medical personnel. However, certain Hocoma products are marketed for home use and must be strictly used according to the recommendations of your medical care provider who is knowledgeable about your specific needs. Consult the User Manual and Hocoma’s website (www.hocoma.com/legalnotes) for appropriate product designation. Failure to obtain and follow the recommendations of your medical care provider may result in serious personal injury.
This information provides details about medical products which may not be available in all countries and may not have received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing herein should be construed as a solicitation or promotion of any product or of an indication of any specific use for any product which is not authorized by the laws and regulations of the country where the reader of this information resides.